Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568465 | 0.79 | CA12 (0.47) | MAPTHPGDRXFP1MAPK1L3MBTL1 | |
| SCHEMBL5567393 | 0.79 | L3MBTL1 (0.47) | MAPTHPGDRXFP1MAPK1L3MBTL1 | |
| SCHEMBL2806608 | 0.78 | MEN1 (0.49) | MAPTMEN1KMT2ARXFP1TDP1 | |
| SCHEMBL5563814 | 0.77 | MAPT (0.51) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL22776736 | 0.75 | MEN1 (0.43) | MAPTMEN1KMT2ARXFP1TDP1 | |
| SCHEMBL5569675 | 0.74 | MAPT (0.57) | MAPTHPGDRXFP1MAPK1RECQL | |
| SCHEMBL540166 | 0.72 | GRM5 (0.52) | MEN1KMT2ARXFP1MAPK1TYR | |
| SCHEMBL540147 | 0.72 | ACHE (0.60) | MEN1KMT2ARXFP1TYRALDH1A1 | |
| SCHEMBL15965364 | 0.72 | L3MBTL1 (0.50) | MAPTHPGDRXFP1MAPK1ALDH1A1 | |
| SCHEMBL6267898 | 0.72 | MAPT (0.63) | MAPTHPGDMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247654-B2 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009895-A1 | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors | TFPI, HABP2, TFPI2 | MAPT 4008/4885HPGD 3724/4885MEN1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.